Cellmid is an Australian biotechnology company committed to contribute to improved patient outcomes by developing a range of therapeutic, prognostic and diagnostic products around midkine. The Company’s disease targets include inflammatory and autoimmune conditions and cancer.
Cellmid holds the largest and most comprehensive portfolio of intellectual property involving midkine and midkine antagonists globally and owns 20 patent families.
Midkine, a heparin binding growth factor, is one of the few novel therapeutic and diagnostic targets with validated roles in the pathogenesis of inflammation, cancer growth and spread.
The Company’s most advanced clinical development program targets the treatment of acute myocardial infarct (AMI or heart attack) utilising the midkine protein and its anti-apoptotic characteristics.
Preclinical programs include anti-midkine antibody therapy for the treatment of rheumatoid arthritis and multiple sclerosis.
CDY is actively out-licensing its broad diagnostic patent portfolio for the early detection, monitoring, prognosis and disease management of cancer. Cellmid is further developing its antagonist programs including its anti-midkine antibodies and small molecule inhibitors with the view to seek out partnerships in the future.